



Louisiana

Endovascular Therapies for Extracranial Vertebral Artery Disease

Policy # 00466

Original Effective Date: 06/17/2015

Current Effective Date: 10/14/2024

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the “Company”), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Note: Extracranial Carotid Angioplasty Stenting is addressed separately in medical policy 00155.

Note: Endovascular Procedures for Intracranial Arterial Disease (Atherosclerosis and Aneurysms) is addressed separately in medical policy 00198.

Services Are Considered Investigational

Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers endovascular therapy, including percutaneous transluminal angioplasty (PTA) with or without stenting, for the management of extracranial vertebral artery disease to be **investigational**.*

Policy Guidelines

The extracranial vertebral artery is considered to be segments V1 to V3 of the vertebral artery from its origin at the subclavian artery until it crosses the dura mater.

Background/Overview

Vertebrobasilar Circulation Ischemia

Ischemia of the vertebrobasilar or posterior circulation accounts for about 20% of all strokes. Posterior circulation strokes may arise from occlusion of the innominate and subclavian arteries, the extracranial vertebral arteries, or the intracranial vertebral, basilar, or posterior cerebral arteries. Compared with carotid artery disease, relatively little is known about the true prevalence of specific causes of posterior circulation strokes, particularly the prevalence of vertebral artery disease. In a report from a stroke registry, Gulli et al (2013) estimated that, in 9% of cases, posterior circulation strokes are due to stenosis of the proximal vertebral artery. Patients who experience strokes or

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Endovascular Therapies for Extracranial Vertebral Artery Disease

Policy # 00466

Original Effective Date: 06/17/2015

Current Effective Date: 10/14/2024

transient ischemic attacks of the vertebrobasilar circulation face a 25% to 35% risk of stroke within the subsequent 5 years. In particular, the presence of vertebral artery stenosis increases the 90-day risk of recurrent stroke by about 4-fold.

Relevant Clinical Anatomy and Pathophysiology

Large artery disease of the posterior circulation may be due to atherosclerosis (stenosis), embolism, dissection, or aneurysms. In about a third of cases, posterior circulation strokes are due to stenosis of the extracranial vertebral arteries or the intracranial vertebral, basilar, and posterior cerebral arteries. The proximal portion of the vertebral artery in the neck is the most common location of atherosclerotic stenosis in the posterior circulation. Dissection of the extracranial or intracranial vertebral arteries may also cause posterior circulation ischemia. By contrast, posterior cerebral artery ischemic events are more likely to be secondary to embolism from more proximal vessels.

The vertebral artery is divided into 4 segments, V1 through V4, of which segments V1, V2, and V3 are extracranial. V1 originates at the subclavian artery and extends to the C5 or C6 vertebrae; V2 crosses the bony canal of the transverse foramina from C2 to C5; V3 starts as the artery exits the transverse foramina at C2 and ends as the vessel crosses the dura mater and becomes an intracranial vessel. The most proximal segment (V1) is the most common location for atherosclerotic occlusive disease to occur, while arterial dissections are most likely to involve the extracranial vertebral artery just before the vessel crosses the dura mater. Compared with the carotid circulation, the vertebral artery system is more likely to be associated with anatomic variants, including a unilateral artery.

Atherosclerotic disease of the vertebral artery is associated with conventional risk factors for cerebrovascular disease. However, risk factors and the underlying pathophysiology of vertebral artery dissection and aneurysms differ. Extracranial vertebral artery aneurysms and dissections are most often secondary to trauma, particularly those with excessive rotation, distraction, or flexion/extension, or iatrogenic injury, such as during cervical spine surgeries. Spontaneous vertebral artery dissections are rare, and in many cases are associated with connective tissue disorders, including Ehlers-Danlos syndrome type IV, Marfan syndrome, autosomal dominant polycystic kidney disease, and osteogenesis imperfecta type I.

Management of Extracranial Vertebral Artery Disease

The optimal management of occlusive extracranial vertebral artery disease is not well-defined. Medical treatment with antiplatelet or anticoagulant medications is a mainstay of therapy to reduce

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Endovascular Therapies for Extracranial Vertebral Artery Disease

Policy # 00466

Original Effective Date: 06/17/2015

Current Effective Date: 10/14/2024

stroke risk. Medical therapy also typically involves risk reduction for classical cardiovascular risk factors. However, no randomized trials have compared specific antiplatelet or anticoagulant regimens.

Surgical revascularization may be used for vertebral artery atherosclerotic disease, but open surgical repair is considered technically challenging due to poor access to the vessel origin. Surgical repair may involve vertebral endarterectomy, bypass grafting, or transposition of the vertebral artery, usually to the common or internal carotid artery. Moderately-sized, single-center case series of surgical vertebral artery repair from 2012 and 2013 have reported overall survival rates of 91% and 77% at 3 and 6 years postoperatively, respectively, and arterial patency rates of 80% after 1 year of follow-up. Surgical revascularization may be used when symptomatic vertebral artery stenosis is not responsive to medical therapy, particularly when bilateral vertebral artery stenosis is present or when unilateral stenosis is present in the presence of an occluded or hypoplastic contralateral vertebral artery. Surgical revascularization may also be considered in patients with concomitant symptomatic carotid and vertebral disease who do not have relief from vertebrobasilar ischemia after carotid revascularization.

The management of extracranial vertebral artery aneurysms or dissections is controversial due to uncertainty about the risk of thromboembolic events associated with aneurysms and dissections. Antiplatelet therapy is typically used; surgical repair, which may include vertebral bypass, external carotid autograft, and vertebral artery transposition to the internal carotid artery, or endovascular treatment with stent placement or coil embolization, may also be used.

Given the technical difficulties related to surgically accessing the extracranial vertebral artery, endovascular therapies have been investigated for extracranial vertebral artery disease. Endovascular therapy may consist of percutaneous transluminal angioplasty, with or without stent implantation.

FDA or Other Governmental Regulatory Approval

U.S. Food and Drug Administration (FDA)

Currently, no endovascular therapies have been approved by the U.S. FDA specifically for treatment of extracranial vertebral artery disease.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Endovascular Therapies for Extracranial Vertebral Artery Disease

Policy # 00466

Original Effective Date: 06/17/2015

Current Effective Date: 10/14/2024

Various stents, approved for use in the carotid or coronary circulation, have been used for extracranial vertebral artery disease. These stents may be self- or balloon-expandable.

Two devices have been approved by the FDA through the humanitarian device exemption process for *intracranial* atherosclerotic disease. This form of FDA approval is available for devices used to treat conditions with an incidence of 4000 or less per year; the FDA only requires data showing "probable safety and effectiveness." Devices with their labeled indications are as follows:

1. Neurolink System[®]‡ (Guidant). "The Neurolink system is indicated for the treatment of patients with recurrent intracranial stroke attributable to atherosclerotic disease refractory to medical therapy in intracranial vessels ranging from 2.5 to 4.5 mm in diameter with $\geq 50\%$ stenosis and that are accessible to the stent system."
2. Wingspan[™]‡ Stent System (Boston Scientific). "The Wingspan Stent System with Gateway PTA [percutaneous transluminal angioplasty] Balloon Catheter is indicated for use in improving cerebral artery lumen diameter in patients with intracranial atherosclerotic disease, refractory to medical therapy, in intracranial vessels with $\geq 50\%$ stenosis that are accessible to the system."

Rationale/Source

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

Vertebral artery diseases, including atherosclerotic stenosis, dissections, and aneurysms, can lead to ischemia of the posterior cerebral circulation. Conventional management of extracranial vertebral artery diseases may include medical therapy (eg, antiplatelet or anticoagulant medications), medications to reduce atherosclerotic disease risk (eg, statins), and/or surgical revascularization. Endovascular therapies have been investigated as an alternative to conventional management.

Summary of Evidence

For individuals who have extracranial vertebral artery stenosis who receive percutaneous transluminal angioplasty (PTA) with or without stent implantation, the evidence includes

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Endovascular Therapies for Extracranial Vertebral Artery Disease

Policy # 00466

Original Effective Date: 06/17/2015

Current Effective Date: 10/14/2024

randomized controlled trials (RCTs) and noncomparative studies. Relevant outcomes are overall survival, symptoms, morbid events, and treatment-related mortality and morbidity. Two RCTs, the Vertebral Artery Ischemia Stenting Trial (VIST) and the Vertebral Artery Stenting Trial (VAST), found no advantage for endovascular intervention compared with best medical therapy alone. Evidence from noncomparative studies has shown that vertebral artery stenting can be performed with high rates of technical success and low periprocedural morbidity and mortality, and that vessel patency can be achieved in a high percentage of cases. However, long-term follow-up has demonstrated high rates of in-stent stenosis. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have extracranial vertebral artery aneurysm(s), dissection(s), or arteriovenous fistula(e) who receive PTA with stent implantation, the evidence includes small case series and reports. Relevant outcomes are overall survival, symptoms, morbid events, and treatment-related mortality and morbidity. The available evidence has indicated that endovascular therapy for extracranial vertebral artery disorders other than stenosis is feasible and may be associated with favorable outcomes. However, given the lack of data comparing endovascular therapies to alternatives, the evidence is insufficient to permit conclusions about the efficacy of endovascular therapy for extracranial vertebral artery aneurysms, dissections, or arteriovenous fistulae. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Supplemental Information

Practice Guidelines and Position Statements

Guidelines or position statements will be considered for inclusion in ‘Supplemental Information’ if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

American Heart Association and American Stroke Association

The American Heart Association and American Stroke Association (2014) issued joint guidelines on prevention of stroke in patients with stroke and transient ischemic attack with recommendations about treatment of extracranial vertebrobasilar disease. These guidelines were updated in 2021 and

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Endovascular Therapies for Extracranial Vertebral Artery Disease

Policy # 00466

Original Effective Date: 06/17/2015

Current Effective Date: 10/14/2024

the most recent recommendations and evidence statements about treatment of extracranial vertebrobasilar disease are listed in Table 1.

Table 1. Guidelines on Stroke Prevention in Patients With Stroke and Transient Ischemic Attack

Recommendation	COR	LOE
"In patients with recently symptomatic extracranial vertebral artery stenosis, intensive medical therapy (antiplatelet therapy, lipid lowering, BP control) is recommended to reduce stroke risk"	I	A
"In patients with ischemic stroke or TIA and extracranial vertebral artery stenosis who are having symptoms despite optimal medical treatment, the usefulness of stenting is not well established"	IIb	B-R
"In patients with ischemic stroke or TIA and extracranial vertebral artery stenosis who are having symptoms despite optimal medical treatment, the usefulness of open surgical procedures, including vertebral endarterectomy and vertebral artery transposition, is not well established"	IIb	C-EO

BP: blood pressure; COR: class of recommendation; LOE: level of evidence; TIA: transient ischemic attack.

Level of Evidence: A: high-quality evidence from more than 1 RCT; B-R: moderate quality of evidence from 1 or more randomized controlled trials; C-EO: consensus of expert opinion based on clinical experience.

American Stroke Association et al

In 2011, a multisociety task force issued guidelines on the management of extracranial vertebral and carotid artery disease, which made the following statement about catheter-based revascularization of extracranial vertebral artery disease: "Although angioplasty and stenting of the vertebral vessels are technically feasible, as for high-risk patients with carotid disease, there is insufficient evidence from randomized trials to demonstrate that endovascular management is superior to best medical management." No specific recommendations were made about endovascular therapies.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Endovascular Therapies for Extracranial Vertebral Artery Disease

Policy # 00466

Original Effective Date: 06/17/2015

Current Effective Date: 10/14/2024

U.S. Preventive Services Task Force Recommendations

Not applicable.

Medicare National Coverage

The Centers for Medicare & Medicaid Services has a national coverage determination addressing the use of percutaneous transluminal angioplasty in the treatment of atherosclerotic obstructive lesions of the lower or the upper extremities (not including the head or neck vessels), of a single coronary artery, of renal arteries, and of arteriovenous dialysis fistulas and grafts. It also addresses the use of percutaneous transluminal angioplasty concurrent with carotid stent placement in U.S. Food and Drug Administration investigational device exemption clinical trials, in U.S. Food and Drug Administration-approved post approval studies, and in patients at high risk for carotid endarterectomy.

The national coverage determination states that all other indications for percutaneous transluminal angioplasty, with or without stenting, to treat obstructive lesions of the vertebral and cerebral arteries remain noncovered.

Ongoing and Unpublished Clinical Trials

A search of [ClinicalTrials.gov](https://clinicaltrials.gov) in April 2024 did not identify any ongoing or unpublished trials that would likely influence this review.

References

1. Gulli G, Marquardt L, Rothwell PM, et al. Stroke risk after posterior circulation stroke/transient ischemic attack and its relationship to site of vertebrobasilar stenosis: pooled data analysis from prospective studies. *Stroke*. Mar 2013; 44(3): 598-604. PMID 23386676
2. Morasch MD, Phade SV, Naughton P, et al. Primary extracranial vertebral artery aneurysms. *Ann Vasc Surg*. May 2013; 27(4): 418-23. PMID 23540677
3. Coleman DM, Obi A, Criado E, et al. Contemporary outcomes after distal vertebral reconstruction. *J Vasc Surg*. Jul 2013; 58(1): 152-7. PMID 23478503
4. Ramirez CA, Febrer G, Gaudric J, et al. Open repair of vertebral artery: a 7-year single-center report. *Ann Vasc Surg*. Jan 2012; 26(1): 79-85. PMID 22176877

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Endovascular Therapies for Extracranial Vertebral Artery Disease

Policy # 00466

Original Effective Date: 06/17/2015

Current Effective Date: 10/14/2024

5. Markus HS, Larsson SC, Kuker W, et al. Stenting for symptomatic vertebral artery stenosis: The Vertebral Artery Ischaemia Stenting Trial. *Neurology*. Sep 19 2017; 89(12): 1229-1236. PMID 28835400
6. Compter A, van der Worp HB, Schonewille WJ, et al. Stenting versus medical treatment in patients with symptomatic vertebral artery stenosis: a randomized open-label phase 2 trial. *Lancet Neurol*. Jun 2015; 14(6): 606-14. PMID 25908089
7. Markus HS, Harshfield EL, Compter A, et al. Stenting for symptomatic vertebral artery stenosis: a preplanned pooled individual patient data analysis. *Lancet Neurol*. Jul 2019; 18(7): 666-673. PMID 31130429
8. Lattanzi S, Brigo F, Di Napoli M, et al. Endovascular treatment of symptomatic vertebral artery stenosis: A systematic review and meta-analysis. *J Neurol Sci*. Aug 15 2018; 391: 48-53. PMID 30103970
9. Xu R, Zhang X, Liu S, et al. Percutaneous transluminal angioplasty and stenting for vertebral artery stenosis. *Cochrane Database Syst Rev*. May 17 2022; 5(5): CD013692. PMID 35579383
10. Markus HS, Larsson SC, Dennis J, et al. Vertebral artery stenting to prevent recurrent stroke in symptomatic vertebral artery stenosis: the VIST RCT. *Health Technol Assess*. Aug 2019; 23(41): 1-30. PMID 31422789
11. Kikuchi T, Ishii A, Nakahara I, et al. Japanese Registry of Neuroendovascular Therapy: extracranial steno-occlusive diseases except for internal carotid artery stenosis. *Neurol Med Chir (Tokyo)*. 2014; 54(1): 40-5. PMID 24257542
12. Sun X, Ma N, Wang B, et al. The long term results of vertebral artery ostium stenting in a single center. *J Neurointerv Surg*. Dec 2015; 7(12): 888-91. PMID 25332411
13. Mohammadian R, Sharifipour E, Mansourizadeh R, et al. Angioplasty and stenting of symptomatic vertebral artery stenosis. Clinical and angiographic follow-up of 206 cases from Northwest Iran. *Neuroradiol J*. Aug 2013; 26(4): 454-63. PMID 24007733
14. Hatano T, Tsukahara T, Miyakoshi A, et al. Stent placement for atherosclerotic stenosis of the vertebral artery ostium: angiographic and clinical outcomes in 117 consecutive patients. *Neurosurgery*. Jan 2011; 68(1): 108-16; discussion 116. PMID 21099720
15. Pham MH, Rahme RJ, Arnaout O, et al. Endovascular stenting of extracranial carotid and vertebral artery dissections: a systematic review of the literature. *Neurosurgery*. Apr 2011; 68(4): 856-66; discussion 866. PMID 21242839
16. Badve MS, Henderson RD, O'Sullivan JD, et al. Vertebrobasilar dissections: case series comparing patients with and without dissecting aneurysms. *J Clin Neurosci*. Nov 2014; 21(11): 2028-30. PMID 24913932

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Endovascular Therapies for Extracranial Vertebral Artery Disease

Policy # 00466

Original Effective Date: 06/17/2015

Current Effective Date: 10/14/2024

17. Kondo R, Ishihara S, Uemiya N, et al. Endovascular Treatment for Acute Ischaemic Stroke Caused by Vertebral Artery Dissection: A Report of Three Cases and Literature Review. *NMC Case Rep J*. 2021; 8(1): 817-825. PMID 35079554
18. Horowitz MB, Miller G, Meyer Y, et al. Use of intravascular stents in the treatment of internal carotid and extracranial vertebral artery pseudoaneurysms. *AJNR Am J Neuroradiol*. Apr 1996; 17(4): 693-6. PMID 8730189
19. Felber S, Henkes H, Weber W, et al. Treatment of extracranial and intracranial aneurysms and arteriovenous fistulae using stent grafts. *Neurosurgery*. Sep 2004; 55(3): 631-8; discussion 638-9. PMID 15335430
20. Herrera DA, Vargas SA, Dublin AB. Endovascular treatment of traumatic injuries of the vertebral artery. *AJNR Am J Neuroradiol*. Sep 2008; 29(8): 1585-9. PMID 18499790
21. Ambekar S, Sharma M, Smith D, et al. Successful treatment of iatrogenic vertebral pseudoaneurysm using pipeline embolization device. *Case Rep Vasc Med*. 2014; 2014: 341748. PMID 25276469
22. Jang HJ, Oh SY, Shim YS, et al. Endovascular treatment of symptomatic high-flow vertebral arteriovenous fistula as a complication after c1 screw insertion. *J Korean Neurosurg Soc*. Oct 2014; 56(4): 348-52. PMID 25371787
23. Shang EK, Fairman RM, Foley PJ, et al. Endovascular treatment of a symptomatic extracranial vertebral artery aneurysm. *J Vasc Surg*. Nov 2013; 58(5): 1391-3. PMID 23561429
24. Takahashi S, Katayama K, Tatsugawa T, et al. A successful hybrid repair for vertebral arteriovenous fistula with extracranial vertebral artery aneurysm. *Ann Vasc Surg*. Jan 2015; 29(1): 126.e5-8. PMID 25304908
25. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*. Jul 2014; 45(7): 2160-236. PMID 24788967
26. Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. *Stroke*. Jul 2021; 52(7): e364-e467. PMID 34024117
27. Brott TG, Halperin JL, Abbara S, et al. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American Stroke Association, American Association of

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Endovascular Therapies for Extracranial Vertebral Artery Disease

Policy # 00466

Original Effective Date: 06/17/2015

Current Effective Date: 10/14/2024

Neuroscience Nurses, American Association of Neurological Surgeons, American College of Radiology, American Society of Neuroradiology, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventional Surgery, Society for Vascular Medicine, and Society for Vascular Surgery. *Circulation*. Jul 26 2011; 124(4): e54-130. PMID 21282504

28. Centers for Medicare & Medicaid Services. National Coverage Determination (NCD) for Percutaneous Transluminal Angioplasty (PTA) (20.7). 2013; <https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=201>.

Policy History

Original Effective Date: 06/17/2015

Current Effective Date: 10/14/2024

- 06/04/2015 Medical Policy Committee review
- 06/17/2015 Medical Policy Implementation Committee approval. New policy.
- 08/03/2015 Coding update: ICD10 Diagnosis code section added; ICD9 Procedure code section removed.
- 06/02/2016 Medical Policy Committee review
- 06/20/2016 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
- 01/01/2017 Coding update: Removing ICD-9 Diagnosis Codes
- 07/06/2017 Medical Policy Committee review
- 07/19/2017 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
- 07/05/2018 Medical Policy Committee review
- 07/11/2018 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
- 05/13/2019 Coding update
- 07/03/2019 Medical Policy Committee review
- 07/18/2019 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
- 07/02/2020 Medical Policy Committee review

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Endovascular Therapies for Extracranial Vertebral Artery Disease

Policy # 00466

Original Effective Date: 06/17/2015

Current Effective Date: 10/14/2024

- 07/08/2020 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
 - 09/02/2021 Medical Policy Committee review
 - 09/08/2021 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
 - 09/01/2022 Medical Policy Committee review
 - 09/14/2022 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
 - 09/07/2023 Medical Policy Committee review
 - 09/13/2023 Medical Policy Implementation Committee approval. No change to coverage.
 - 10/05/2023 Coding update
 - 09/05/2024 Medical Policy Committee review
 - 09/11/2024 Medical Policy Implementation Committee approval. No change to coverage.
- Next Scheduled Review Date: 09/2025

Coding

The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®)†, copyright 2023 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Endovascular Therapies for Extracranial Vertebral Artery Disease

Policy # 00466

Original Effective Date: 06/17/2015

Current Effective Date: 10/14/2024

contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

Code Type	Code
CPT	0075T, 0076T, 37246
HCPCS	No codes
ICD-10 Diagnosis	All related diagnoses

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

- A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or
- B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
 - 1. Consultation with technology evaluation center(s);
 - 2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
 - 3. Reference to federal regulations.

‡ Indicated trademarks are the registered trademarks of their respective owners.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Endovascular Therapies for Extracranial Vertebral Artery Disease

Policy # 00466

Original Effective Date: 06/17/2015

Current Effective Date: 10/14/2024

NOTICE: If the Patient's health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.

NOTICE: Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.